[Glitazones clinical data: an update].
The thiazolidinediones (or glitazones) were recently added to the oral treatments for type 2 diabetes. Several recent studies, either in in vitro models or in animal models, lead to a better understanding of their mechanism of action. Recent, long term, controlled clinical studies, permit to define better their place and their condition of use (including adverse event prevention), as a monotherapy, or in association with metformin or a sulfonylurea when these drugs failed to achieve an optimal glycemic control. The beneficial metabolic effects of glitazones, generate great hopes for the prevention of the progressive beta-pancreatic cell function decline observed in type 2 diabetics, and possibly to prevent and/or to delay type 2 diabetes in high at-risk subjects. This review describe and discuss the most recent studies and their results.
Guerci
B
B
Service de Diabétologie, Maladies Métaboliques et Maladies de la Nutrition, CIC/INSERM, CHU de Nancy, Hôpital Jeanne d'Arc, 54201 Toul Cedex, BP 303, France. b.guerci@chu-nancy.fr
D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000517:prevention & control; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects / Q000378:metabolism; D045162:Thiazolidinediones / Q000627:therapeutic use*
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D045162:Thiazolidinediones